Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer
- Min Sun†1,
- Haibin Song†1,
- Shuyi Wang1,
- Chunxiao Zhang1,
- Liang Zheng1,
- Fangfang Chen1,
- Dongdong Shi1,
- Yuanyuan Chen1,
- Chaogang Yang1,
- Zhenxian Xiang1,
- Qing Liu1,
- Chen Wei1 and
- Bin Xiong1Email authorView ORCID ID profile
© The Author(s). 2017
Received: 25 January 2017
Accepted: 17 March 2017
Published: 29 March 2017
With persistent inconsistencies in colorectal cancer (CRC) miRNAs expression data, it is crucial to shift toward inclusion of a “pre-laboratory” integrated analysis to expedite effective precision medicine and translational research. Aberrant expression of hsa-miRNA-195 (miR-195) which is distinguished as a clinically noteworthy miRNA has previously been observed in multiple cancers, yet its role in CRC remains unclear.
In this study, we performed an integrated analysis of seven CRC miRNAs expression datasets. The expression of miR-195 was validated in The Cancer Genome Atlas (TCGA) datasets, and an independent validation sample cohort. Colon cancer cells were transfected with miR-195 mimic and inhibitor, after which cell proliferation, colony formation, migration, invasion, and dual luciferase reporter were assayed. Xenograft mouse models were used to determine the role of miR-195 in CRC tumorigenicity in vivo.
Four downregulated miRNAs (hsa-let-7a, hsa-miR-125b, hsa-miR-145, and hsa-miR-195) were demonstrated to be potentially useful diagnostic markers in the clinical setting. CRC patients with a decreased level of miR-195-5p in tumor tissues had significantly shortened survival as revealed by the TCGA colon adenocarcinoma (COAD) dataset and our CRC cohort. Overexpression of miR-195-5p in DLD1 and HCT116 cells repressed cell growth, colony formation, invasion, and migration. Inhibition of miR-195-5p function contributed to aberrant cell proliferation, migration, invasion, and epithelial mesenchymal transition (EMT). We identified miR-195-5p binding sites within the 3’-untranslated region (3′-UTR) of the human yes-associated protein (YAP) mRNA. YAP1 expression was downregulated after miR-195-5p treatment by qRT-PCR analysis and western blot.
Four downregulated miRNAs were shown to be prime candidates for a panel of biomarkers with sufficient diagnostic accuracy for CRC in a clinical setting. Our integrated microRNA profiling approach identified miR-195-5p independently associated with prognosis in CRC. Our results demonstrated that miR-195-5p was a potent suppressor of YAP1, and miR-195-5p-mediated downregulation of YAP1 significantly reduced tumor development in a mouse CRC xenograft model. In the clinic, miR-195-5p can serve as a prognostic marker to predict the outcome of the CRC patients.
KeywordsHsa-miRNA-195(miR-195) YAP1 Colorectal cancer (CRC) Epithelial mesenchymal transition (EMT) Prognosis Biomarker
Colorectal cancer (CRC) has been the fourth leading cause of cancer death worldwide for several decades . The 5-year survival rate for localized stage CRC is 90%, whereas as CRC spreads to the regional lymph nodes or distant parts of the body, the 5-year survival rate plunges from 71% to 13% in the United States . These malignancies are ascribed to accumulation of genetic alterations, including dissemination of proto-oncogenes, losing or inactivating of tumor suppressor genes, and EMT, which ultimately lead to tumor evolution and progression [3–7].
Using the miRNA expression profile, dysregulated microRNAs (miRNA/miR) in CRC can be identified. Specific miRNAs have been suggested as biomarkers for CRC pathogenesis, metastasis, recurrence, and as potential therapeutic targets . Previous research, by examining a series of CRC microRNAs expression profile data, recommended several deregulated miRNAs, but most failed to identify efficient miRNA biomarkers. Furthermore, few mechanistic studies address the question of how miRNA drives the alterations of the hallmark CRC signaling pathways . For a collective set of deregulated miRNAs, experimental validation is still lacking, and the potential mRNA targets of these miRNAs and their regulatory mechanisms remain unknown. The multicenter sequencing of 1893 carcinoma/normal paired samples revealed that miR-195-5p was a tumor-suppressing miRNA and was downregulated in tumor tissues . Since predicted targets of miR-195-5p were enriched for the Hippo/YAP signaling pathway, we hypothesize that miR-195-5p may function by targeting the YAP1 mRNA. Recent studies showed that YAP and its transcriptional coactivator with PDZ-binding motif (TAZ) function as a nexus on the crosstalk of multiple signaling pathways, and therefore can be potential therapeutic targets as the chief downstream effectors of the Hippo pathway in a variety of cancers [11–15]. It was documented that YAP and TAZ overexpression resulted in a trend of shorter survival time by multivariate analysis in CRC . However, there have been few studies on miRNAs that regulate the oncogenic alterations in the Hippo signaling pathway.
We performed an integrated analysis and identified significantly disturbed miRNAs by using microRNA sequencing data in primary tumors and paired adjacent normal tissue (PANT), both derived from the CRC patients. We further validated aberrant expression patterns of these miRNAs in the TCGA-COAD dataset . We distinguished miR-195-5p as a clinically noteworthy miRNA in CRC as found in lung cancer . We confirmed that the miR-195-5p level was high in patients with favorable survival in TCGA, and may play a critical role in CRC tumorigenesis. Ectopic expression of miR-195-5p could significantly reduce proliferation, migration, invasion, and EMT in two colon cancer cell lines, DLD1 and HCT116. We showed for the first time that the full-length 3′-UTR of the human YAP1 mRNA was a direct target of miR-195-5p. These data offer a plausible mechanism accounting for the tumor-suppressing function of miR-195-5p, further supporting the notion that the miR-195-5p/YAP1/EMT axis can be the therapeutic focus for eliminating CRC tumorigenesis .
Search strategy and data collection, preprocessing, and normalization
Public microarray repositories were curated to search through the PubMed, GEO (accession numbers GSE33124, GSE35982, GSE33122, GSE35834, GSE33125, GSE33123, GSE68306, GSE35834, GSE41655, GSE41012, GSE73178, GSE54632, GSE68377, GSE48267, GSE54088, GSE45349, GSE38389, GSE28364, GSE7828, GSE35602, GSE10259 and GSE49246) and Array Express (accession numbers E-MTAB-96, E-GEOD-35834, E-GEOD-28364 and E-MTAB-2479) through September 2015 (the full-detailed search strategy and search terms are shown in Additional file 1: Table S1). The reference sections of the regained studies were analyzed for additional pertinent papers. The checklist and pipeline for properly organizing the integrated analysis were decided as recommended by Ramasamy, via the reporting guidelines of microarray meta-analysis . Only original experimental studies that screened for different miRNAs between CRC and PANT in humans were the first choice for inclusion. Additional criteria for selection dictated that the included datasets should contain at least 30 samples of CRC and PANT correspondingly. Exclusion criteria included: (1) repeated reports by the same institute, hospital; (2) a non-expression gene chip; and (3) a non-whole-genome chip. All datasets were normalized individually on the base-2 logarithm by Robust Multi-Array Average (RMA) and Linear Models for Microarray (LIMMA) package and annotated by converting different probe IDs to gene IDs. All miRNA names were standardized according to miRBase version 17 via miRBase Tracker and consisted with TCGA for subsequent validation . Any probe that did not map to a gene ID was removed as viral miRNAs or non-miRNA probes.
Integrated analysis of miRNAs expression datasets
To identify differentially expressed (DE) miRNAs between CRC and PANT, we used MetaOmics software (http://www.pitt.edu/~tsengweb/MetaOmicsHome.htm) executed as a MetaDE package . For integrated analysis, the mean and standard deviation (SD) filter thresholds were specified as 10%. Considering the different stringencies of the methods, Fisher’s method was performed for statistical analysis of significance: a modified t test and permutation method were used to extrapolate the P values . One-sided tests were applied to classify the upregulated or downregulated DE miRNAs. A P value less than 0.05 was considered statistically significant for the DE miRNAs.
Integrated-signature miRNA analysis of TCGA
The results of integrated analysis of miRNAs expression datasets were validated in the TCGA datasets. TCGA-COAD miRNA data and clinical data (level 3) of the corresponding patients (tumor and/or adjacent normal tissue) were downloaded from the TCGA Data portal (up to May 20, 2016). The expression analyses were carried out using BRB-ArrayTools (version 4.5, National Cancer Institute, Bethesda, MD, USA) .
Target prediction and functional analysis of miRNA
The presumed targets of integrated-signature miRNAs, especially the most significant has-miR-195, were identified by four different target prediction algorithms: TargetScan v7.1 (http://www.targetscan.org/vert_71/), miRDB (http://www.mirdb.org/miRDB/), DIANA-TarBase v7.0 (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index/), and PicTar (http://pictar.mdc-berlin.de/cgi-bin/PicTar_vertebrate.cgi). Unique genes with target sites in 3′UTR were incorporated. To assess the prospective functions of the most significant has-miR-195, we discharged the Kyoto Encyclopedia of Genes and Genomes (KEGG) using the Database for Annotation, Visualization and Integrated Discovery (DAVID) . The P value that narrated KEGG pathway enrich the target gene less than 0.05 was defined as the cutoff criterion.
Sixty human CRC tissues and PANT (distance to cancer > 5 cm) were acquired from patients who had been diagnosed with primary CRC by pathological assessment of tissues and undergone surgeries with complete prognostic information at the Zhongnan Hospital of Wuhan University between January 2011 and December 2015. No local or systemic neoadjuvant radiotherapy, or/and chemotherapy and targeted therapy were managed. The study was approved by the Research Ethics Committee of Wuhan University (Wuhan, Hubei, PR China). Informed consents were obtained from all participating patients.
Cell culture and transfection of miR-195 mimic, inhibitor, and siRNA of target gene
Human colon cancer cell lines DLD1 and HCT116, and normal intestinal epithelium cell line NCM460 were purchased from the Cell Bank of Wuhan University. Cells were cultured in DMEM medium (Gibco, USA) containing 2 mmol/L glutamine, 10% heat-inactivated (56 °C, 30 min) fetal calf serum, streptomycin (100 U/mL) and penicillin (100 U/mL), and maintained in a humidified atmosphere of 5% CO2 at 37 °C. Hsa-miR-195 mimic and mimic negative control (NC), hsa-miR-195 inhibitor, and inhibitor negative control (NC) were purchased from RiboBio Co., Ltd. (Guangzhou, China). Cells were cultured in complete medium at least 24 h before transfection. Cells were washed by phosphate-buffered saline (PBS, pH 7.4) before transient transfection with 50 nM miR-195-5p mimic or miR mimic NC, 100 nM miR-195-5p inhibitor or miR inhibitor NC. Three siRNA duplexes targeting human YAP1 (GenBank accession no. NM_001130145.2) were synthesized by RiboBio Company (Guangzhou, China). Transfections were performed by Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s protocol with RNA oligonucleotides at a final concentration of 50 nM.
Total RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted using a Trizol reagent (Invitrogen). For the qRT-PCR detection of mature miR-195-5p expression, we purchased the Bulge-Loop™ miRNA qRT-PCR Primer Set and Control Primer Set (RiboBio, Guangzhou, China). RNA (2 μg) was converted into cDNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo). QRT-PCR was accomplished using the FastStart Universal SYBR Green Master (Rox) (Roche) in the ABI PRISM® 7300 real-time PCR system (Applied Biosystems, Foster City, CA, USA). GADPH and U6 were used as endogenous controls. We used melting curves to monitor non-specific amplifications. Relative expression level was computed using 2-ΔΔCt method. The primer sequences used are listed in Supplemental Experimental Procedures.
Tumor formation in BALB/c nude mice and immunohistochemistry
BALB/c athymic nude mice (female, 4 – 6 weeks old and 16 – 20 g) were purchased from Hubei Research Center of Laboratory Animals (Wuhan, China). All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Wuhan University. To establish the CRC cancer xenograft model, 5 × 106 DLD1 cells were suspended in 150 μL PBS and inoculated subcutaneously into the flanks of the nude mice. After 8 days, the transplanted nude mice were randomly divided into two groups (n = 6 each). MiR-195-5p agomir or miR agomir NC (RiboBio Co., Ltd, Guangzhou, China) was directly injected into the implanted tumor at the dose of 2 nmol/30μL PBS per mouse every 4 days for seven times. Tumor dimension was measured by length (L) and width (W) with a caliper every 4 days, and the volumes were calculated using the formula: (L × W2)/2. Mice were sacrificed by cervical dislocation after being anaesthetized with 10% chloral hydrate at day 36, and the tumors were excised and snap-frozen for protein and RNA extraction. Immunohistochemistry of the tumor tissues was performed as described previously .
The significance of the differences between the groups was determined with an ANOVA test or Student’s t test, and P < 0.05 was considered statistically significant. The results were expressed as the mean ± SD from at least three independent experiments. Kaplan-Meier method and Cox's proportional hazards regression model were used to calculate overall survivals, and the differences were analyzed by a log-rank test. Receiver operating characteristic (ROC) curve analysis was performed using the code of Mihaly (Additional file 2: Supplemental R script) by R Software (version 3.2.3; http://www.r-project.org) .
Supplemental experimental procedures include the following information: dual luciferase reporter assays, BrdU immunofluorescence assay, colony formation assay, CCK8 assay, wound healing assay in vitro, transwell migration/invasion assay, transfection reagents, primers, western blot analysis, and antibody (Additional file 3: Supplemental Experimental Procedures).
Integrated analysis of seven CRC miRNAs expression datasets identified 21 significantly deregulated miRNAs in CRC
Integrated-signature miRNAs showed clinical prognostic significance in CRC patients
Baseline characteristics of patients by miRNA assessment set
TCGACOAD test cohort
Independent validation cohort
(n = 240)
(n = 60)
60 years or younger
Older than 60 years
Pathologic M stage
12 or more
Less than 12
Follow-up time (months)
Preoperative serum CEA level
Univariate and multivariate analyses of clinicopathological characteristics, miR-195-5p, and YAP1 with overall survival in TCGA COAD cohort and independent validation cohort
HR (95% Cl)
HR (95% CI)
TCGA COAD testing set (n = 240)
Gender(male vs. female)
Age, years (≥median vs. < median)
Nodes count (12 or more vs. fewer than 12)
Lymphatic invasion (present vs. absent)
Pathologic M stage (present vs. absent)
TNM stage (III and IV vs. I and II)
Vascular invasion (present vs. absent)
Preoperative CEA level
(≥5 μg/mL vs. <5 μg/mL)
Hsa-miR-195 (≥median vs. < median)
YAP1 (≥median vs. < median)
Independent validation cohort (n = 60)
Gender(male vs. female)
Age, years (≥median vs. < median)
Nodes count (12 or more vs. fewer than 12)
Lymphatic invasion (present vs. absent)
Pathologic M stage (present vs. absent)
TNM stage (III and IV vs. I and II)
Vascular invasion (present vs. absent)
Preoperative CEA level
(≥5 μg/mL vs. <5 μg/mL)
Hsa-miR-195 (≥median vs. < median)
YAP1 (≥median vs. < median)
Functional enrichment and target prediction of miR-195
Significantly, in spite of the presence of biological and technical confounding factors, such as the differences in sample cohorts, treatments, and microarray technologies, in all eight independent CRC expression microarrays, our results indicated the importance of miR-195 expression in human CRC (Fig. 2d). We conducted target prediction for validated miR-195 with high-stringency. Target genes were obtained from both prediction algorithms and experimentally supported databases. The counts of predicted targets, experimentally validated targets, prediction-based consensus targets, and 71 consensus target genes were summarized (Fig. 2e, Additional file 11: Table S8). In addition, we performed KEGG pathway analysis to elucidate the potential biological functions of miR-195 integrated-signature. Interestingly, the top KEGG pathways enriched for the miR-195 targets were mainly associated with cancer-specific pathways (Additional file 12: Table S9), including the Hippo signaling pathway, proteoglycans in cancer, viral carcinogenesis, pathways in cancer, and prostate cancer (Fig. 2f). In previous analysis, the Hippo signaling pathway was significantly enriched for the predicted targets of miR-195-5p (P = 6.47E-05) (Additional file 13: Figure S2). Taken together, these results indicate that deregulated miR-195 expression plays a critical role in human CRC.
Downregulation of miR-195-5p is concomitant with upregulation of YAP1 in primary human CRC
Since the Hippo pathway emerged in our previous KEGG analysis for the miR-195 targets, it is conceivable that miR-195 may directly regulate this pathway during CRC tumorigenesis. Meanwhile, the protein-protein interaction network (PPI) suggested that YAP1 is the hub gene of the miR-195 targets (Additional file 14: Figure S3). YAP1 is the pivot in the Hippo signaling pathway leading to potent oncogenicity, and can promote cell growth, migration, invasion, and EMT in many tumors including CRC. Therefore, we also examined YAP1 expression in this sample cohort comprising the 60 human CRC and PANT. Both qRT-PCR and western blot results showed that YAP1 was significantly upregulated in CRC compared with PANT (Fig. 3d). Significantly, the miR-195-5p level was inversely correlated with the YAP1 level in the tumors as calculated by Pearson’s correlation (R 2 = 0.531, P = 4.02E − 11) (Fig. 3e), suggesting that miR-195-5p may downregulate YAP1 in CRC (Fig. 3e). Of note, Kaplan–Meier and Cox’s proportional hazards regression model also revealed that patients with high levels of YAP1 had shorter overall survivals (Fig. 3f, Table 2).
MiR-195-5p inhibits proliferation and colony formation of colon cancer cells
MiR-195-5p inhibits migration and invasion of colon cancer cells
MiR-195-5p targets human YAP1 and inhibits YAP1 in colon cancer cells
To confirm the direct regulation of miR-195-5p on YAP1 expression, we transfected DLD1 and HCT116 cells with miR-195-5p mimic, miR mimic NC, miR-195-5p inhibitor, and miR-195-5p inhibitor NC. Both qRT-PCR and western blotting revealed that the YAP1 level was reduced in miR-195-5p-expressing cells, while its level was restored in miR-195-5p inhibitor-treated cells (Fig. 6d–f). The conversion from epithelial cells to mesenchymal cells, characterized by spindle-type cell morphology, was observed in HCT116 cells treated with miR-195-5p inhibitor (Additional file 15: Figure S4). So far, the results suggest that miR-195-5p negatively regulates YAP1 levels in CRC cells. Additionally, expressions of TAZ, Vimentin, ZEB2, and SMAD3 protein were also negatively regulated by miR-195-5p, while E-cadherin was positively regulated by miR-195-5p, suggesting the negative regulations of miR-195-5p on the Hippo pathway and EMT in CRC cells.
Silence of YAP1 expression inhibits colon cancer cell growth, clone formation, invasion, migration, and rescue assay
We next evaluated the potential tumorigenicity of YAP1 in CRC. Silence of YAP1 expression by siRNA significantly inhibited the expression of YAP (Additional file 16: Figure S5). Moreover, loss of YAP1 expression also contributed to inhibition of colon cancer cell (DLD1 and HCT116 cells) growth (Additional file 16: Figure S5a), clone formation (Additional file 16: Figure S5b–c), invasion, and migration (Additional file 16: Figure S5d–e). These results further verified the powerful tumorigenicity of YAP1 in CRC. These results indicated that the anti-cancer and reverse EMT efficacy of miR-195-5p is partly attributed to its inhibitory role on YAP, which was confirmed by qRT-PCR and western blot of YAP1 (Additional file 16: Figure S5f-g) in DLD1 cells.
MiR-195-5p suppresses tumor growth in vivo
Integrated analysis, a conscientious approach to unify cross-platform standardization of gene profiling and overlook the unavailability of raw data, has been used to identify differentially expressed genes at the mRNA and miRNA level in CRC [29, 30]. Chen et al. overcame the drawback of lack of conformity among miRNA expression profiling studies in CRC by means of directly combining the ranks of prioritized miRNA lists but not re-analyzing the raw miRNAs profiles . However, they failed to consider the effects of small sample size and heterogeneity of the individual studies because they included 17 studies whose sample size was under 30 pairs in total 24 studies. Conversely, our integrated analysis of the raw data of the seven studies whose sample size is over 30 pairs reliably reveals the differential miRNAs across various platforms.
Our current study supports the validity and effectiveness of this integrated strategy. Firstly, reduced expression of miR-195-5p in primary CRC was revealed independently by both integrated analysis and TCGA-COAD validation analysis, suggesting miR-195-5p can be an effective diagnostic and prognostic marker in the clinical setting. Secondly, ectopic expression of miR-195-5p in colon cancer cell lines considerably decreased cell growth, migration, and invasion. Thirdly, miR-195-5p can directly regulate expression of YAP1 by targeting its 3′-UTR. It can inhibit expression of YAP1, TAZ, Vimentin, ZEB2, and SMAD3, and promote E-cadherin expression in colon cancer cells. Finally, miR-195-5p suppressed tumor growth in vivo.
The goals of the current study were to identify the candidate driver miRNAs in CRC through meta-analysis of multiple datasets of miRNA expression arrays and to validate their biological functions and significance for clinical diagnosis and prognostic prediction. The integrated analysis method described here was designed to exclude the low precision studies, account for biases inherent in single studies, and nominate prevalently dysregulated miRNAs. Taking into account these considerations, we have included seven miRNAs expression data from seven different platforms in CRC using the MetaDE method, which provided options for gene merging, matching across studies, and gene filtering . We screened 10 upregulated and 11 downregulated miRNAs in CRC samples using moderated t test and Fisher’s method by summarizing -log(P value). In addition, we validated and obtained 4 downregulated miRNAs (i.e., hsa-let-7a, hsa-miR-125b, hsa-miR-145, and hsa-miR-195) from over 250 tumors from the TCGA-COAD database which granted us the opportunity to systematically analyze the potential molecular mechanisms associated with the pathophysiology of CRC. These four miRNAs seem to have a context-specific value as a diagnostic marker of CRC. For hsa-let-7a, hsa-miR-125b, and hsa-miR-145, previous reports have shown their downregulation was correlated with the antitumor effect in CRC [31, 32]. In this study, we found that hsa-let-7a, hsa-miR-125b, and hsa-miR-145 were downregulated in CRC and correlated with improved survivals of CRC patients. Only the low level of miR-195 in tumors was substantially correlated with reduced overall survivals of CRC patients, suggesting miR-195 may negatively regulate CRC progression.
MiR-195 as a tumor suppressor has been reported in various types of cancer. It is a member of paralogous, evolutionarily conserved miRNAs termed the miR-15/107 family that has been suggested to have considerable potential in prognostic prediction [33–38]. Soon et al. found aberrant expression of miR-195 could indicate a poorer prognosis in adrenocortical carcinoma . Li et al. found that extracellular vesicles delivering miR-195 to intrahepatic cholangiocarcinoma could decrease the tumor size and improve survivals in a rat model . Luo et al. found miR-195 might tender a novel tactic for the diagnosis and treatment of breast cancer patients . In our study, we confirmed that miR-195 was downregulated in CRC tissues, which was significantly correlated with poor survivals of CRC patients. We investigated the mechanism of miR-195-5p-mediated regulations on colon cancer cells and found that over-expression of miR-195-5p markedly inhibited cellular proliferation and invasion of CRC cells. Supported by miRNA target analysis and luciferase reporter assays, we propose that miR-195-5p targets the 3′-UTR of YAP1 mRNA and inhibits YAP expression, leading to proliferative inhibition in CRC cells. Furthermore, the present study also shed light on the potential role of miR-195-5p in CRC metastasis, where ectopic expression of miR-195-5p could reduce cell migration and invasion and promote expression of the EMT marker, E-cadherin. To our knowledge, this is the first meta-analysis that reveals the detailed mechanism where loss of miR-195-5p leads to malignant progression of CRC via unleashed expression of YAP1.
It is well known that Hippo signaling controls cell growth and differentiation . In several tumors, aberrant activation of the Hippo/YAP signaling pathway represents one of the most important mechanisms accounting for oncogenic progression and invasiveness, and has been recognized as a prognostic factor of poor outcome [11, 43–52]. Major signal transducers of the Hippo pathway were proposed as prognostic factors in colorectal cancer [53, 54]. We also identified the Hippo signaling pathway as being enriched in the prediction analysis of the miR-195-5p targets. Experimentally, we verified that the Hippo pathway core effector YAP1 mRNA 3′-UTR had two conserved miR-195-5p cognate sites. Interestingly, we also found that loss of miR-195-5p accelerated YAP expression and promoted nuclear accumulation of YAP and EMT in vitro [19, 55, 56]. Hence, major players in this pathway may be tightly regulated by miR-195-5p in the colorectum, and miR-195-5p restoration could target YAP/TAZ/EMT pathway to suppress CRC progression. Furthermore, it is likely that other molecules or signaling pathways will be discovered that are also targeted by miR-195-5p in CRC. Future work will focus on revealing additional functions of miR-195-5p in CRC carcinogenesis and progression.
In summary, we have performed integrated analysis of miRNomes of human normal colorectum and CRC tissues, which provided us rich resources for exploring the roles of miRNAs in CRC. Four downregulated miRNAs (hsa-let-7a, hsa-miR-125b, hsa-miR-145, and hsa-miR-195) can be potentially useful diagnostic markers in the clinic. Among them, only miR-195 is inversely correlated with overall survival in CRC patients. We have demonstrated that miR-195-5p is dramatically downregulated in human CRC tissues compared with normal colorectal tissues. Moreover, upregulation of miR-195-5p suppresses proliferation, migration, invasion, and EMT of colon cancer cells through targeting the YAP1 mRNA 3′-UTR. Collectively, miR-195-5p suppresses tumor cell growth in vitro and tumorigenicity in vivo. Our study may serve as rational for targeting the miR-195-5p/YAP interaction in a novel therapeutic application to medicate CRC patients.
Adjacent normal tissue
Epithelial mesenchymal transition
Gene Expression Omnibus
Paired adjacent normal tissue
Protein-protein interaction network
Quantitative reverse transcription polymerase chain reaction
Transcriptional coactivator with PDZ-binding motif
The Cancer Genome Atlas
The authors would like to thank Prof. Min Zhao from Basic Medical Sciences of Wuhan University and Xinyi Zhao from Biological Information Sciences of Zhejiang University, for analyzing the miRNAs expression data. They also thank Wenlou Liu from Wuhan University for his technical assistance with the immunohistochemistry. They also thank Biqin Tan from Zhejiang University for the critical reading of the manuscript.
This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81572874). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
The data supporting our findings can be found in the supplementary data.
MS,BX,HS, and SW participated in the research design. MS, HS, CZ, LZ, and ZX conducted the experiments. MS, HS, CZ, and LX contributed the new reagents or analytic tool. MS, MZ, XZ, and HS performed the data analysis. MS,BX,HS, and SW wrote or contributed to the writing of the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The research protocol was reviewed and approved by the Ethics Committee of Wuhan University, and informed consent was obtained from all participants included in the study, in agreement with institutional guidelines.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.View ArticlePubMedGoogle Scholar
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.View ArticlePubMedGoogle Scholar
- El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, Zaffaroni N. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10(1):19.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, et al. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. J Hematol Oncol. 2016;9:1.View ArticlePubMedPubMed CentralGoogle Scholar
- Chai ZT, Zhu XD, Ao JY, Wang WQ, Gao DM, Kong J, Zhang N, Zhang YY, Ye BG. Ma DN et al: microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. J Hematol Oncol. 2015;8:56.View ArticlePubMedPubMed CentralGoogle Scholar
- Dzikiewicz-Krawczyk A, Macieja A, Maly E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, Strauss E, Nowak J. Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol. 2014;7:43.View ArticlePubMedPubMed CentralGoogle Scholar
- Dzikiewicz-Krawczyk A. MicroRNA-binding site polymorphisms in hematological malignancies. J Hematol Oncol. 2014;7:83.View ArticlePubMedPubMed CentralGoogle Scholar
- Roy S, Levi E, Majumdar AP, Sarkar FH. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu P, Zhu Y, Sun B, Xiao Z. Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile. Sci Rep. 2016;6:20616.View ArticlePubMedPubMed CentralGoogle Scholar
- Slattery ML, Herrick JS, Pellatt DF, Stevens JR, Mullany LE, Wolff E, Hoffman MD, Samowitz WS, Wolff RK. MicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa: variations in miRNA expression and disease progression. Carcinogenesis. 2016;37(3):245–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Yimlamai D, Fowl BH, Camargo FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491–501.View ArticlePubMedPubMed CentralGoogle Scholar
- Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S, et al. microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer. 2014;13:97.View ArticlePubMedPubMed CentralGoogle Scholar
- Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, et al. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016;7(18):25930–48.PubMedPubMed CentralGoogle Scholar
- Zhang K, Qi HX, Hu ZM, Chang YN, Shi ZM, Han XH, Han YW, Zhang RX, Zhang Z, Chen T, et al. YAP and TAZ take center stage in cancer. Biochemistry-Us. 2015;54(43):6555–66.View ArticleGoogle Scholar
- Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. Plos One. 2013;8(6):e65539.View ArticlePubMedPubMed CentralGoogle Scholar
- Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ, Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L, et al. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance. Oncotarget. 2015;6(28):25093–108.View ArticlePubMedPubMed CentralGoogle Scholar
- Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guanjian L, Yujie L, Yunchao H. MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett. 2014;347(1):65–74.View ArticlePubMedGoogle Scholar
- Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui A, Wu T, Liu CY, Cui L. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2016;35(21):2789–800.View ArticlePubMedGoogle Scholar
- Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. Plos Med. 2008;5(9):e184.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Peer G, Lefever S, Anckaert J, Beckers A, Rihani A, Van Goethem A, Volders PJ, Zeka F, Ongenaert M, Mestdagh P, et al. miRBase tracker: keeping track of microRNA annotation changes. Database (Oxford). 2014;2014:1–8.
- Wang X, Kang DD, Shen K, Song C, Lu S, Chang LC, Liao SG, Huo Z, Tang S, Ding Y, et al. An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics. 2012;28(19):2534–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012;40(9):3785–99.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao Y, Simon R. BRB-ArrayTools Data Archive for human cancer gene expression: a unique and efficient data sharing resource. Cancer Inform. 2008;6:9–15.PubMedPubMed CentralGoogle Scholar
- da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.View ArticleGoogle Scholar
- Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, Fang W, Xiong B, Wan Y, Dong C. A protective role by interleukin-17F in colon tumorigenesis. Plos One. 2012;7(4):e34959.View ArticlePubMedPubMed CentralGoogle Scholar
- Mihaly Z, Kormos M, Lanczky A, Dank M, Budczies J, Szasz MA, Gyorffy B. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat. 2013;140(2):219–32.View ArticlePubMedGoogle Scholar
- Lu S, Li J, Song C, Shen K, Tseng GC. Biomarker detection in the integration of multiple multi-class genomic studies. Bioinformatics. 2010;26(3):333–40.View ArticlePubMedGoogle Scholar
- Chan SK, Griffith OL, Tai IT, Jones SJ. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev. 2008;17(3):543–52.View ArticlePubMedGoogle Scholar
- Chen X, Shi K, Wang Y, Song M, Zhou W, Tu H, Lin Z. Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. Oncotarget. 2015;6(35):37544–56.PubMedPubMed CentralGoogle Scholar
- Gattolliat CH, Uguen A, Pesson M, Trillet K, Simon B, Doucet L, Robaszkiewicz M, Corcos L. MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas. Eur J Cancer. 2015;51(3):409–20.View ArticlePubMedGoogle Scholar
- Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008;68(15):6416–24.View ArticlePubMedGoogle Scholar
- Zhao Q, Cao J, Wu YC, Liu X, Han J, Huang XC, Jiang LH, Hou XX, Mao WM, Ling ZQ. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. Am J Cancer Res. 2015;5(5):1692–705.PubMedPubMed CentralGoogle Scholar
- Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y, Liu Y, Li S, Liang Z, Xu X, et al. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. J Transl Med. 2015;13:289.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang N, Wei H, Yin D, Lu Y, Zhang Y, Zhang Q, Ma X, Zhang S. MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a. Tumour Biol. 2016;37(4):4711–20.View ArticlePubMedGoogle Scholar
- Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z, Liu T. Hu F: miR-195 is a key regulator of Raf1 in thyroid cancer. Onco Targets Ther. 2015;8:3021–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Furuya K, Sasaki A, Tsunoda Y, Tsuji M, Udaka Y, Oyamada H, Tsuchiya H, Oguchi K. Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231. Hum Cell. 2016;29(2):76–82.View ArticlePubMedGoogle Scholar
- Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD. Zeng YR et al: miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 2015;21(21):4922–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ. Robinson BG et al: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 2009;15(24):7684–92.View ArticlePubMedGoogle Scholar
- Li L, Piontek K, Ishida M, Fausther M, Dranoff JA, Fu R, Mezey E, Gould SJ, Fordjour FK, Meltzer SJ et al. Extracellular vesicles carry microRNA 195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. 2017;65(2):501–14.
- Luo Q, Wei C, Li X, Li J, Chen L, Huang Y, Song H, Li D, Fang L. MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep. 2014;31(3):1096–102.PubMedPubMed CentralGoogle Scholar
- Irvine KD. Integration of intercellular signaling through the Hippo pathway. Semin Cell Dev Biol. 2012;23(7):812–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21(11):2580–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Ehmer U, Sage J. Control of proliferation and cancer growth by the Hippo signaling pathway. Mol Cancer Res. 2016;14(2):127–40.View ArticlePubMedGoogle Scholar
- Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, Yu FX, Sun Y, Yuan H, et al. Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest. 2015;125(5):2123–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Park J, Jeong S. Wnt activated beta-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells. Oncotarget. 2015;6(33):34658–68.PubMedPubMed CentralGoogle Scholar
- He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. Embo Mol Med. 2015;7(11):1426–49.View ArticlePubMedPubMed CentralGoogle Scholar
- Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros Jr A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015;13(4):e19–29.PubMedGoogle Scholar
- Wang J, Wang H, Zhang Y, Zhen N, Zhang L, Qiao Y, Weng W, Liu X, Ma L, Xiao W, et al. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. Cell Signal. 2014;26(5):1048–59.View ArticlePubMedGoogle Scholar
- Sylvester KG, Colnot S. Hippo/YAP, beta-catenin, and the cancer cell: a “menage a trois” in hepatoblastoma. Gastroenterology. 2014;147(3):562–5.View ArticlePubMedGoogle Scholar
- Xiao W, Wang J, Ou C, Zhang Y, Ma L, Weng W, Pan Q, Sun F. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochem Biophys Res Commun. 2013;439(2):167–72.View ArticlePubMedGoogle Scholar
- Wang DY, Wu YN, Huang JQ, Wang W, Xu M, Jia JP, Han G, Mao BB, Bi WZ. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 2016;35(1):47.View ArticlePubMedPubMed CentralGoogle Scholar
- Wierzbicki PM, Rybarczyk A. The Hippo pathway in colorectal cancer. Folia Histochem Cytobiol. 2015;53(2):105–19.View ArticlePubMedGoogle Scholar
- Liang K, Zhou G, Zhang Q, Li J, Zhang C. Expression of hippo pathway in colorectal cancer. Saudi J Gastroenterol. 2014;20(3):188–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21–45.View ArticlePubMedGoogle Scholar
- Qi Q, Li DY, Luo HR, Guan KL, Ye K. Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. Proc Natl Acad Sci U S A. 2015;112(23):7255–60.View ArticlePubMedPubMed CentralGoogle Scholar